Solomon Moshkevich, the President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, has sold a significant portion of his company stock, according to a recent filing with the Securities and Exchange Commission. The executive sold a total of 80,000 shares at prices ranging from $90.3369 to $91.0604, netting over $7.2 million.
The transactions, which took place on April 16, 2024, were executed under a pre-arranged trading plan known as Rule 10b5-1, which allows company insiders to set up a trading schedule in advance to avoid accusations of insider trading. Moshkevich's sales were made at a weighted average price, with individual sales prices varying within a specified range.
The first batch of shares sold amounted to 26,511, with a weighted average price of $90.3369 per share. In a separate transaction on the same day, Moshkevich sold an additional 53,489 shares at a weighted average price of $91.0604 per share. The transactions were disclosed in footnotes, indicating that prices for the shares sold ranged from $89.73 to $90.72 for the first set, and from $90.73 to $91.48 for the second set of shares.
Following these sales, Solomon Moshkevich still holds a significant number of shares in Natera, with the latest report showing 117,560 shares remaining in his possession. The sales represent a notable change in the executive's holdings in the company but still leave him with a substantial investment in Natera's future.
Natera, headquartered in Austin, Texas, specializes in genetic testing and diagnostics, providing services that contribute to advances in the medical field. The company's stock performance and insider transactions are closely watched by investors who see such activities as an indicator of the company's health and the confidence that executives have in its prospects.
The filing was signed on behalf of Moshkevich by Tami Chen, Attorney-in-Fact, on April 17, 2024.
InvestingPro Insights
Natera Inc .'s (NASDAQ:NTRA) recent financial performance and market valuation metrics provide a mixed picture for investors. While the company has experienced a high return over the last year, with a 1 Year Price Total Return of 79.88%, it also trades at a high Price / Book multiple of 14.25 as of the last twelve months ending Q4 2023. This suggests that the stock may be priced optimistically relative to the company's book value.
The company's Revenue Growth has been impressive, with a 43.2% increase in the quarterly figures for Q4 2023, indicating strong sales performance. However, it's important to note that analysts do not expect Natera to be profitable this year, with a negative P/E Ratio of -25.09 for the same period. These InvestingPro Data points can help investors understand the company's growth trajectory juxtaposed against its current lack of profitability.
Despite the lack of short-term profitability, Natera operates with a moderate level of debt and its liquid assets exceed its short-term obligations, which may provide some financial stability for the company. For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available that could further inform investment decisions. To explore these insights, visit InvestingPro and discover how many more tips are listed for Natera.
For those interested in a deeper dive into Natera's financials and market performance, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.